Answers are grounded in this paper and cite their sources.
// Stefan Langhammer 1 and Joachim Scheerer 1 1 Life Science Consulting, Hirschweg, Burgwedel, Germany Correspondence to: Stefan Langhammer, email: // Keywords : NSCLC, targeted therapy, EGFR, angiogenesis Received : December 16, 2016 Accepted : March 13, 2017 Published : March 29, 2017 Abstract In the light of current treatment developments for non-small cell lung cancer (NSCLC), the idea of a plastic cellular tumorigenic network bound by key paracrine signaling pathways mediating resistances to targeted therapies is brought forward. Based on a review of available preclinical and clinical data in NSCLC combinational approaches to address drivers of this network with marketed drugs are discussed. Five criteria for selecting drug combination regimens aiming at its disruption and thereby overcoming resistances are postulated.
No takes yet. Share an insight, caveat, or question.
Langhammer et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: